Company Overview of Rimonyx Pharmaceuticals, Ltd.
Rimonyx Pharmaceuticals, Ltd. engages in the discovery and development of drugs targeted at glycosaminoglycan and protein interactions. Its RX-111, an orally delivered small molecule drug for inflammatory bowel disease, is slated to enter Phase I clinical trials in the second quarter of 2005. Rimonyx Pharmaceuticals was founded by Paul Gregor in 2002. The company is based in Ness-Ziona, Israel.
Kiryat Weizmann Science Park
Sapir Street 7
Founded in 2002
972 8 940 4593
972 8 940 0917
Key Executives for Rimonyx Pharmaceuticals, Ltd.
Similar Private Companies By Industry
|Abital Pharma Pipelines Ltd.||Middle East/Africa|
|Active PX Ltd.||Middle East/Africa|
|Advanced Inhalation Technology Ltd.||Middle East/Africa|
|Angio B Ltd.||Middle East/Africa|
|Antaki Center for Herbal Medicine Ltd.||Middle East/Africa|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|Rush University||United States|
|The Advertising Council, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Rimonyx Pharmaceuticals, Ltd., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.